A derivative of Mycobacterium smegmatis , which carries only one functional rRNA ( rrn ) operon, was used to isolate mutants resistant to the ribosome-targeted antibiotic linezolid. Isolation and characterization of linezolid-resistant clones revealed two classes of mutants. Ribosomes from class I mutants are resistant to oxazolidinones in an in vitro peptidyl transferase assay, indicating that resistance maps to the ribosome component. In contrast, ribosomes from class II mutants show wild-type susceptibility to a linezolid derivative in vitro , pointing to a non-ribosomal mechanism of resistance. Introduction of a wildtype ribosomal RNA operon into linezolid-resistant strains restored linezolid sensitivity in class I mutants, indicating that resistance (i) maps to the rRNA and (ii) is recessive. Sequencing of the entire rrn operon identified a single nucleotide alteration in 23S rRNA of class I mutant strains, 2447G AE AE AE AE T ( Escherichia coli numbering). Introduction of mutant rrl 2447T into M. smegmatis rrn -resulted in a linezolidresistant phenotype, demonstrating a cause-effect relationship of the 2447G AE AE AE AE T alteration. The 2447G AE AE AE AE T mutation, which renders M. smegmatis linezolid resistant, confers lethality in E. coli . This finding is strong evidence of structural and possibly functional differences between the ribosomes of Gram-positive and Gram-negative bacteria. In agreement with the results of the in vitro assay, class II mutants show a wild-type sequence of the complete rRNA operon. The lack of cross-resistance of the class II mutants to other antibiotics suggests a resistance mechanism other than activation of a broad-spectrum multidrug transporter.
Introduction
Linezolid, (S)-N-{[3-fluoro-4-(4-morphinyl)phenyl]-2-oxo-5-oxazolidinyl} methyl acetamine (see Fig. 1A ), is a representative of a new class of antibiotics, the oxazolidinones (Shinabarger, 1999; Norrby, 2001) . These drugs inhibit protein synthesis both in vivo (Eustice et al ., 1988) and in vitro . Linezolid has activity against a wide range of Gram-positive and Gram-negative bacteria (Corti et al ., 2000) .
Linezolid binds to the large ribosomal subunit, and its binding site within the 50S ribosomal subunit overlaps with those of peptidyl transferase inhibitors lincomycin and chloramphenicol . However, oxazolidinones seem to have a different mode of action. It has been suggested that oxazolidinones interfere with the assembly of the 70S preinitiation complex (Shinabarger et al ., 1997; Swaney et al ., 1998) or with elongation of translation (Matassova et al ., 1999) . More recent data indicate that oxazolidinones target the ribosomal P site (Aoki et al ., 2002) . Consistent with a unique mode of action, linezolid does not show significant cross-resistance with other antibiotics (Brickner et al ., 1996; Zurenko et al ., 1996; Xiong et al ., 2000; Zurenko et al ., 2001) .
Similar to other antibiotics targeting protein synthesis (Cundliffe, 1990; Schluenzen et al ., 2001) , oxazolidinones are assumed to interact directly with the rRNA component of the ribosome. Most microorganisms carry multiple copies of ribosomal RNA operons in their genome, thus preventing isolation of recessive mutations within rrn conferring drug resistance. Initial investigations in Staphylococcus aureus containing six rRNA gene copies suggested that linezolid resistance might occur rarely in clinical isolates (Murray et al ., 1998) . In contrast, linezolidresistant mutants were readily obtained in the single rRNA allelic archaeon Halobacterium halobium (Kloss et al ., 1999) . However, the unusual physiology and genetics of the halophilic archaeon H. halobium makes it difficult to extrapolate these results to the pathogenic eubacteriathe target of linezolid.
In order to get insights into the interaction of linezolid with the eubacterial ribosome and to investigate a possible species-specific idiosyncrasy of ribosome-drug binding, we used an experimental model that is significantly different from H. halobium . We investigated here the mechanisms of linezolid resistance in the Gram-positive eubacterium Mycobacterium smegmatis. M. smegmatis has several characteristics that make it a particular useful model for studying ribosomal function and ribosome-drug interaction: (i) its physiology and genetics resemble that of Gram-positive pathogenic bacteria; (ii) M. smegmatis is amenable to genetic manipulations (Sander et al ., 1997; Prammananan et al ., 1999; Böttger et al ., 2001) ; (iii) a genetically engineered derivative of M. smegmatis , M. smegmatis rrn -, with a single functional rrn operon is available (Sander et al ., 1996) , allowing isolation of rRNA mutations mediating a resistant phenotype irrespective of a dominant or recessive nature of the genetic alteration; (iv) ribosomes suitable for structural and functional analysis can be prepared (Xiong et al ., 2001) .
We found that resistance to linezolid can be mediated by mutations in ribosomal RNA as well as by non-ribosomal mechanisms. Comparative mutational analyses revealed a significant difference in the spectrum of tolerated mutations and therefore in possible mechanisms of drug resistance as well as in the structure and function of ribosomes in Gram-positive and Gramnegative eubacteria.
Results

Generation of linezolid-resistant mutants
For generation of linezolid-resistant (LinR) mutants, an engineered derivative of M. smegmatis , M. smegmatis rrn -, containing a single functional rrn operon (Sander et al ., 1996) ) corresponding to the frequency of single point mutations in M. smegmatis . Therefore, in the majority of mutants, resistance was likely to be conferred by single point mutations.
Physiological characterization of mutants
Determination of the drug resistance levels revealed the presence of two classes of mutants: class I mutants with a MIC of 64.0-128.0 m g ml -1 (10 out of 48 mutants investigated); and class II mutants exhibiting lower resistance with a MIC of 4.0-8.0 m g ml -1 (38 out of 48 mutants investigated) ( Table 1 ).
The difference in the level of linezolid resistance exhibited by the two classes of mutants was accompanied by differences in their growth rate. On non-selective agar plates, class II mutants formed colonies comparable in size to those of the wild type, whereas class I mutants formed much smaller colonies, indicating slower growth characteristics. This was confirmed by liquid culture experiments in which class I mutants exhibited slow growth rates in comparison with wild type or class II mutants (Table 1 ). These differences in growth rate between class I and class II mutants were also observed on selective, linezolid-containing agar plates (data not shown).
Molecular mechanisms of resistance in class I mutants
Previous investigations have suggested that alterations in rRNA are the predominant mechanism mediating linezolid resistance ( Fig. 2) (Kloss et al ., 1999; Xiong et al ., 2000; Gonzales et al ., 2001; Prystrowsky et al ., 2001; Tsiodras et al ., 2001; Jones et al ., 2002) . In order to investigate whether alterations in rRNA are involved in drug resistance of class I and/or class II mutants, a wild-type rRNA operon was introduced into the chromosome of mutant cells. The LinR mutants were transformed with vector pMV361-H-rRNA, an E. coli/Mycobacterium shuttle vector that integrates once into the mycobacterial chromosome and expresses a functional rRNA wild-type operon (Sander et al ., 1997) . Different effects were observed in class I and class II mutants: transformation with pMV361-H-rRNA restored sensitivity to linezolid in class I mutants, but did not affect the linezolid-resistant phenotype of class II mutants (Table 1 ). This result suggests that linezolid resistance in class I mutants results from a recessive rrn mutation. In contrast, mutations in class II mutants either represent dominant rrn alterations or are located outside rrn .
To determine the mutational alteration underlying linezolid resistance, the entire sequence of the functional rrn operon (composed of 16S rRNA, 23S rRNA and 5S rRNA) of a class I mutant was deduced and compared with the wild-type sequence. A single nucleotide change at 23S rRNA position 2447G AE T ( E. coli numbering) was found. Mutations conferring linezolid resistance have previously been mapped to rrl positions located in the 2000-2600 segment of 23S rRNA ( E. coli numbering) (Kloss et al ., 1999; Xiong et al ., 2000; Prystrowsky et al ., 2001) . In order to investigate resistance-related sequence alterations, all 10 class I mutants were sequenced in this region. Sequencing results supported the conclusions drawn from physiological characterization: the 2447G AE T alteration was found in all class I mutants; this particular alteration was the only mutation observed in this region.
RecA-mediated homologous recombination (Prammananan et al ., 1999 ) was used to demonstrate a cause-effect relationship for mutation rrl 2447G AE T. Plasmid pMV361-Gm-rrl 2447T carries a non-functional rrn fragment of 1.1 kbp containing rrl mutation 2447T; plasmid pMV361-Gm-rrl2447G, carrying the homologous fragment with a wild-type rrl2447G, served as a control. After transformation of M. smegmatis rrn -with pMV361-Gm-rrl2447T, linezolid-resistant recombinants were readily observed after plating in the presence of linezolid (frequency of 1.38 ¥ 10 -6
). Occurrence of linezolidresistant recombinants was both RecA dependent and dependent on the 2447G AE T mutation (Table 2) . Recombinant rrl2447T strains showed the same characteristics as the spontaneous class I mutant strains, with respect to both antibiotic resistance and growth rate (see Table 1 ). Transformation of plasmid pMV361-Gm-rrl2447T into M. smegmatis mc 2 155 SMR5, carrying two functional rrn operons, did not result in linezolid-resistant transformants (<10 -8
). These results allow us to conclude that: (i) a 2447G AE T mutation causes linezolid resistance in M. smegmatis; (ii) linezolid resistance mediated by mutation rrl2447T is recessive.
A non-ribosomal mechanism of resistance in class II mutants
In contrast to class I mutants, sequencing the G2447 region in 38 class II mutants did not show any alteration in this region of 23S rRNA. To investigate potential mutations outside rrl region 2000-2600, the entire rrn operon of three linezolid-resistant isolates with a 2447 wild-type allele was sequenced; no sequence alteration was found. These results indicate that linezolid resistance in class II mutants is not the result of alterations in the sequence of ribosomal RNA.
The absence of mutations in the rRNA of class II mutants did not exclude the possibility that one of the multiple ribosomal proteins may carry an amino acid sequence alteration causing the resistance. Therefore, in order to test further whether the resistance of class II mutants to linezolid was ribosome associated, we tested the effect of the drug on the activity of the ribosome in vitro. Although mutational studies place the linezolid binding site within the ribosomal peptidyl transferase centre :aph obtained after RecA-mediated recombination between the chromosomal functional rrnA operon and vector pMV361-Gm-rrl2447T, carrying a non-functional rrl fragment comprising mutation rrl2447G AE T. (Swaney et al., 1998; Kloss et al., 1999; Xiong et al., 2000) , linezolid is a poor inhibitor of the ribosomal peptidyl transferase activity in in vitro assays (Kloss et al., 1999; Xiong et al., 2000) . Thus, we used a derivative of linezolid, PNU-176798 (Fig. 1B) , which was shown to inhibit the peptidyl transferase reaction efficiently (Aoki et al., 2002) . Before the use of PNU-176798 in the in vitro assay, we verified that wild-type M. smegmatis is sensitive to the drug and that the mutants, irrespective of whether classified as class I or class II mutants, exhibit resistance to the drug (see Table 1 ). Ribosomes were prepared from wildtype and mutant M. smegmatis cells using a standard procedure (Spedding, 1990) , and their peptidyl transferase activity was tested in a 'fragment assay' (Monro and Marcker, 1967) . Ribosomes prepared from class I mutants showed notable resistance to PNU-176798 in vitro, whereas peptidyl transferase activity of the ribosomes prepared from class II mutants was as sensitive to PNU-176798 inhibition as that of the ribosomes prepared from the wild-type cells (Fig. 3) . This observation strongly suggests that the resistance mutation(s) in class II mutants do(es) not affect interaction of PNU-176798 and, by inference, of linezolid with the ribosome and therefore probably lies outside the genes encoding ribosomal components. The susceptibility of class II mutants to a variety of ribosomal drugs was determined. No difference from the parental rrn -strain was found ( Table 3 ), indicating that resistance in class II mutants involves a mechanism other than activation of a broad-spectrum multidrug transporter.
Oxazolidinone resistance in class II mutants does not reduce fitness
Class I mutants that carry the G2447T mutation exhibit a decreased growth rate in liquid culture and on agar plates. In contrast, the class II mutants show growth characteristics comparable with that of the wild type. In order to investigate more accurately whether class II mutants have to pay a fitness cost for acquiring resistance to linezolid, the changes in relative fitness were examined in a competition growth experiment.
As shown in Fig. 4 , co-growth of the wild type and the class II mutant for 48 generations did not notably change the ratio of the two types of cells in the mixed population (the cost of resistance was <1.5% per generation). This result demonstrates that class II mutations do not bear a significant fitness cost, at least when cells are grown in rich laboratory media.
Discussion
The detailed mechanism of action of oxazolidinones has still to be determined. However, it is clear that its site of action is located on the large ribosomal subunit and that its binding site is composed primarily, or maybe exclusively, of ribosomal RNA Kloss et al., 1999; Matassova et al., 1999; Xiong et al., 2001) . The main evidence for this came from findings that multiple resistance mutations isolated in the halophilic archaeon H. halobium localized exclusively to 23S rRNA (Kloss et al., 1999) . Although linezolid resistance mutations in clinical isolates of Enterococcus faecium, Enterococcus faecalis and Staphylococcus aureus have been reported (Murray et al., 1998; Shinabarger, 1999; Gonzales et al., 2001; Prystrowsky et al., 2001; Tsiodras et al., 2001) , these mutants appear with a relatively low frequency because of the presence of multiple rrn operons in most bacterial pathogens. Multiplicity of rRNA-encoding genes not only complicates the isolation and characterization of linezolid-resistant mutants but blurs the studies on mechanisms of drug action and resistance in yet another way. Thus, in enterococci, linezolid resistance was found to be associated with various rrn mutations (at corresponding E. coli positions G2505, C2512, G2513, G2576 and C2610) (Prystrowsky et al., 2001) . In one of the mutant strains, as many as four different rrl alterations have been observed. In such a case, the multiplicity of rrn alleles makes it difficult to assess the role of a particular mutation in drug resistance. The repeated passage of strains in the presence of increasing drug concentrations might have resulted in the successive accumulation of mutational alterations leading to either increased linezolid resistance or compensation for the fitness cost of a primary resistance mutation (Nagaev et al., 2001) . To overcome the multiple rrn allele problem and in order to study the site and mode of action of oxazolidinones, model organisms have been exploited that offer the advantage of having only one copy of the rRNA operon in the chromosome. The majority of linezolid resistance mutations have been described so far for the halophilic archaeon H. halobium (Kloss et al., 1999) , which allowed mapping of the linezolid binding site in the vicinity of the ribosomal peptidyl transferase centre. In spite of the usefulness of such information for modelling the ribosome binding site of the drug and for understanding its mode of action, the use of an organism belonging to an evolutionary domain other than Bacteria imposes important limitations on transferring the data obtained to the antibiotic target, i.e. human pathogenic Gram-positive bacteria. Indeed, very few of the linezolid resistance mutations described for the archaeon H. halobium have been found so far in pathogenic bacteria (Prystrowsky et al., 2001) .
These considerations underline the usefulness of the M. smegmatis model that we used in this study. The genetically engineered strain of M. smegmatis rrn -, which carries only one rRNA operon in its chromosome, allows the generation of linezolid-resistant mutants in a one-step selection. Indeed, a number of mutant isolates were readily obtained by a simple plating of cells on selective antibiotic media. All the independently isolated class I mutants contained the same mutation G2447T.
Molecular genetic techniques were used to demonstrate that the rrl2447T mutation causes resistance to linezolid. After transformation with pMV361-H-rrn2447T, RecA-mediated gene conversion readily resulted in LinR recombinants in strain M. smegmatis rrn -(carrying a single functional rrn operon); no such drug-resistant recombinants were obtained in M. smegmatis mc 2 155 SMR5, which carries two wild-type rrn operons. The resistance phenotype appears to be recessive, as the LinR phenotype of spontaneous resistant mutants was reverted to a susceptible phenotype after a second, wild-type rrn operon was introduced into the chromosome. This latter observation is important because, in pathogens containing multiple rrn alleles, single point mutations in rRNA genes would not render cells resistant to linezolid and, therefore, the appearance of linezolid resistance as a result of the target site modification should be delayed.
The recessive nature of the 2447T mutation explains previous results obtained with E. coli. The predominant linezolid resistance mutation found in E. coli was A2032G, whereas the 2447T mutation introduced into the cells on a multicopy plasmid conferred only marginal resistance at a high fitness expense (Xiong et al., 2000) . The low level of resistance rendered by the 2447T mutation in E. coli could result from the fact that wild-type rRNA transcribed from the chromosomal unmutated rrn alleles in those cells accounted for approximately one-third of the rRNA, thus masking the recessive resistance conferred by ribosomes carrying the G2447U mutation.
Investigation of linezolid-resistant mutants in several other species, i.e. H. halobium, E. faecalis and E. faecium (in vitro and clinical strains) so far has not resulted in isolation of a rrl2447T mutant (for a summary of resistance mutations observed, see Fig. 2 ). Linezolid represents a unique example of a drug for which the spectrum of resistance mutations exhibits a very strong speciesspecific bias. Only a few of the multiple linezolid resistance H. halobium mutations that were clustered in the central loop of domain V of 23S rRNA were found in other organisms (Prystrowsky et al., 2001) . Similarly, the main linezolid resistance mutation found in E. coli, G2032A, never appeared in either linezolid-resistant Gram-positive bacterial strains or H. halobium. Conversely, mutations found in Gram-positive bacteria, G2447T or G2576T, were never found in resistant organisms outside the Gram-positive branch of the bacterial tree. The simplest explanation for such a pronounced species-specific bias of drug resistance mutations includes the possibility that some of the linezolid resistance mutations that are permissive in one species may cause significant loss of function in the other. Alternatively, the precise position of the ribosome-bound antibiotic may differ somewhat in different ribosomes, resulting in different contributions of a specific drug-RNA contact to drug binding and may therefore give rise to different mutational spectra. Escherichia coli cells expressing a mixed population of wild-type and mutant G2447U ribosomes exhibited a low level of linezolid resistance and showed a notably reduced growth rate (Xiong et al., 2000) . Repeated attempts to generate an E. coli strain that only carries rrl2447U mutant ribosomes but no wild-type ribosomes failed, suggesting that the G2447T alteration confers recessive lethality in E. coli (Thompson et al., 2001; L. Xiong and A. S. Mankin, unpublished results) . The G2447U mutation is located in the catalytic domain of the 23S rRNA that is involved in peptide bond formation (Nissen et al., 2000) . Although these findings with E. coli are in general in line with the hypothesis that G2447 is important for catalysis of peptidyl transfer (Nissen et al., 2000) , they are in contrast to the results reported here that single rRNA allelic M. smegmatis mutants carrying the G2447T mutation and containing a homogeneous population of mutant ribosomes are viable. Mutant M. smegmatis cells showed a somewhat reduced growth rate; however, the extent of protein synthesis carried out by the mutant ribosomes was sufficient to support growth in liquid culture and colony formation on agar plates. The finding that the nucleotide identity at position 2447 of 23S rRNA is dispensable for ribosome function in vivo in M. smegmatis argues against its critical role in peptidyl transfer Thompson et al., 2001; Xiong et al., 2001) .
The discrepancy between lethality of the G2447T alteration in E. coli and the viability of this particular mutation in M. smegmatis suggests structural differences between ribosomes of M. smegmatis and E. coli, which may reflect a more general difference between the ribosomes of Gram-positive and Gram-negative microorganisms. Regardless of whether peptidyl transfer is by positioning, chemical catalysis or a combination thereof, the observation that the G2447T alteration is tolerated in M. smegmatis but not in E. coli points to additional 23S rRNA elements contributing to substrate positioning or conformational rearrangements.
All the previously characterized linezolid resistance mutations were located in rRNA genes. Therefore, it was surprising to find that, in addition to the mutants carrying the G2447U mutation in 23S rRNA, a second class of mutants was observed in M. smegmatis. An in vitro peptidyl transferase assay with isolated ribosomes indicated that resistance in these mutants must result from a mechanism different from target site alteration, as the ribosomes isolated from these mutants behaved essentially like wild-type ribosomes in the presence of the drug. It is likely that linezolid resistance in these mutants is caused by either decreased drug uptake into the bacterial cell or increased active efflux of the drug (caused, for example, by altering the specificity or activity of an efflux transporter). Indeed, overexpression of efflux pumps may cause linezolid resistance in E. coli (A. S. Mankin, unpublished). The class II mutants did not show increased resistance to a number of other antibiotics (see Table 3 ), indicating that this mutation is either activating a pump with a narrow specificity or affecting another cell function. Additional experiments are required to locate the site of mutation. Independent of the mechanism conferring class II resistance, this genetic alteration does not confer a significant cost of resistance (growth disadvantage in the absence of the drug), at least under laboratory conditions, and therefore might be expected to be found in some clinical drug-resistant isolates.
Experimental procedures
Strains and plasmids
Strains and plasmids used in this investigation are listed in Table 4 . E. coli XL1-Blue was used for all initial cloning experiments and propagated in LB medium (containing 1% casein hydrolysate, 0.5% yeast extract and 0.5% NaCl; Difco). M. smegmatis was grown in Erlenmeyer flasks in brain-heart infusion (BHI) medium supplemented with Tween 80 (final concentration 0.05%) to avoid clumping (Sander et al., 1996) .
Mycobacterium smegmatis rrn -is a derivative of M. smegmatis mc 2 155 (Snapper et al., 1990) , in which one of the two ribosomal RNA operons (rrnB) was functionally inactivated by substituting parts of the 16S rRNA and 23S rRNA gene with an aph cassette (Sander et al., 1996) .
Concentrations of ampicillin and gentamicin used for E. coli were 100 mg ml -1 and 15 mg ml -1 respectively. For experiments with M. smegmatis, gentamicin and hygromycin were used at concentrations of 5 mg ml -1 and 25 mg ml 
Construction of plasmid pMV361-Gm-rrl2447
A 1.1 kbp fragment comprising the 3¢ end of 23S rRNA was generated with primers 86 and 206 (for list of primers, see Supplementary material) using genomic DNAs of wild-type M. smegmatis and M. smegmatis 2447T mutant strain as a Sander et al. (1997 This study pMV-361-Gm-rrl2447T This study template. Subsequently, polymerase chain reaction (PCR) amplicons were digested with HpaI and BstEII. Fragments were cloned into the unique HpaI site of plasmid pMV361-Gm producing plasmids pMV361-Gm-rrl2447G and pMV361-Gm-rrl2447T respectively.
Transformation of M. smegmatis
Mycobacterium smegmatis was transformed essentially as described previously (Sander et al., 1996) . In short, cells were grown to an OD 600 of 0.5-1.0 at 37∞C with constant shaking, cooled on ice for 1.5 h and harvested by centrifugation. Cells were resuspended in ice-cold glyerol (10% v/v) and washed several times with ice-cold glycerol (10% v/v). Transformation was performed in a Bio-Rad gene pulser II with 100 ml of competent cells and 1 mg of plasmid DNA at the following settings: 2.5 kV, 25 mF, 1000 Ohm. Cells were resuspended in 1 ml of BHI-Tween medium and incubated at 37∞C for 3 h before plating. Transformants were obtained after 3-5 days of incubation at 37∞C. Transformants were propagated in the presence of gentamicin or hygromycin respectively.
Selection of linezolid-resistant mutants
Spontaneous linezolid-resistant mutants of M. smegmatis were selected by spreading 5 ¥ 10 8 -5 ¥ 10 9 cells on BHI plates containing linezolid at a concentration of 8 mg ml -1 . Plates were incubated for up to 10 days at 37∞C. Colonies were purified by restreaking on antibiotic-free BHI plates and stored until further use.
Recombinant transformants carrying pMV361-Gmrrl2447T were spread on medium containing linezolid. The frequency of RecA-mediated homologous recombination (Prammananan et al., 1999) was calculated by dividing the number of linezolid-resistant colonies by the number of gentamicin-resistant colonies.
In vitro ribosome assay
Ribosomes were prepared from exponentially growing M. smegmatis cells using a standard protocol (Spedding, 1990) . The peptidyl transferase activity of ribosome was tested using a 'fragment reaction' assay with formyl-Met-tRNA Met as a donor and puromycin as an acceptor substrate (Monro and Marcker, 1967 ), 0.8 mM ribosomes, 1 mM puromycin and varying concentrations of antibiotic PNU-176798, a linezolid derivative that efficiently inhibits peptidyl transferase reaction. Before addition to the reaction mix, the ribosomes were preincubated for 5 min at 37∞C in the reaction buffer. The drug was added, and the ribosome-drug mixture was incubated for an additional 5 min at 37∞C (corresponding amount of DMSO -a solvent in which the drug was dissolved -was added to the control reactions). Formyl-[
S]-Met-tRNA
Met and puromycin were added subsequently, and the reaction was initiated by the addition of 25 ml of methanol (final methanol concentration 33%). After incubation on ice for 30 min, the reaction was terminated by the addition of 10 ml of 10 M KOH. The mixture was incubated for 20 min at 37∞C and neutralized by the addition of 200 ml of 1 M KH 2 PO 4 . The reaction product, formyl-methionylpuromycin, was extracted with 1 ml of ethyl acetate and counted in a scintillation counter (Beckman LS 6000IC). Background radioactivity of the control reaction lacking puromycin was subtracted from all the values.
Physiological characterization of mutants
Minimal inhibitory concentrations were determined in a volume of 200 ml in a microtitre plate by diluting a freshly grown culture of M. smegmatis to an optical density (OD 600 ) of 0.025 in BHI medium in the presence of different concentrations of the drug. Antibiotic-free BHI medium served as a control. MIC (defined as the lowest concentration that completely inhibits growth of bacteria) was read after 3 days of incubation at 37∞C.
The growth rate of M. smegmatis strains in the exponential growth phase was determined by growing strains in a 250 ml Erlenmeyer flask containing 50 ml of BHI-Tween at 37∞C with constant shaking. Optical density (OD 600 ) was determined every 3 h.
The cost of resistance was determined by competition growth between the drug-resistant mutant and the drugsusceptible parental strain. Drug-susceptible and drugresistant strains were mixed in ratio of 1:1 in antibiotic-free BHI medium to result in an OD of 0.05. The mixture was incubated further at 37∞C with constant shaking and, every 24 h, 0.05 ml of the grown culture was transferred into 5 ml of fresh BHI medium for growth. Aliquots were plated after every third passage on drug-free BHI medium or on BHI medium containing linezolid (8.0 mg ml -1
). The number of parental drug-susceptible cells was calculated as the total number of bacterial cells minus the number of drug-resistant bacterial cells. Serial dilutions of each aliquot were plated in triplicate, and a weighted mean according to the level of dilution was used for analysis. The difference in fitness between the two competing strains at time t was computed with the following formula (Sander et al., 2002): ( 1) where r t and s t denote the absolute number of resistant and drug-susceptible cells at time t respectively. S t is called the selection coefficient at time t. The quotient of the ratios of the cell numbers was standardized with the exponent 1/ 24, because cell numbers were determined approximately every 24th generation. The cost per generation (cpg) was calculated as: 
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